Report Detail
Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
- RnM4619572 |
- 26 September, 2024 |
- Global |
- 106 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man"s life. BPH most often occurs during this second growth phase.
According to our (Global Info Research) latest study, the global Benign Prostatic Hyperplasia (BPH) Drugs market size was valued at US$ 3553 million in 2023 and is forecast to a readjusted size of USD 4425 million by 2030 with a CAGR of 3.2% during review period.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report is a detailed and comprehensive analysis for global Benign Prostatic Hyperplasia (BPH) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Benign Prostatic Hyperplasia (BPH) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2019-2030
Global Benign Prostatic Hyperplasia (BPH) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2019-2030
Global Benign Prostatic Hyperplasia (BPH) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2019-2030
Global Benign Prostatic Hyperplasia (BPH) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Benign Prostatic Hyperplasia (BPH) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Benign Prostatic Hyperplasia (BPH) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA, Mylan, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Benign Prostatic Hyperplasia (BPH) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Market segment by Application
Hospitals
Drugstores
Others
Major players covered
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with price, sales quantity, revenue, and global market share of Benign Prostatic Hyperplasia (BPH) Drugs from 2019 to 2024.
Chapter 3, the Benign Prostatic Hyperplasia (BPH) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benign Prostatic Hyperplasia (BPH) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Benign Prostatic Hyperplasia (BPH) Drugs.
Chapter 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Alpha-Blocker
- 1.3.3 Phosphodiesterase Type-5 Inhibitors
- 1.3.4 Others
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Hospitals
- 1.4.3 Drugstores
- 1.4.4 Others
- 1.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size & Forecast
- 1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2019 & 2023 & 2030)
- 1.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (2019-2030)
- 1.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (2019-2030)
2 Manufacturers Profiles
- 2.1 Eli Lilly
- 2.1.1 Eli Lilly Details
- 2.1.2 Eli Lilly Major Business
- 2.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Eli Lilly Recent Developments/Updates
- 2.2 GlaxoSmithKline
- 2.2.1 GlaxoSmithKline Details
- 2.2.2 GlaxoSmithKline Major Business
- 2.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 GlaxoSmithKline Recent Developments/Updates
- 2.3 Astellas Pharma
- 2.3.1 Astellas Pharma Details
- 2.3.2 Astellas Pharma Major Business
- 2.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Astellas Pharma Recent Developments/Updates
- 2.4 Sanofi
- 2.4.1 Sanofi Details
- 2.4.2 Sanofi Major Business
- 2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Sanofi Recent Developments/Updates
- 2.5 Pfizer
- 2.5.1 Pfizer Details
- 2.5.2 Pfizer Major Business
- 2.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Pfizer Recent Developments/Updates
- 2.6 Abbott
- 2.6.1 Abbott Details
- 2.6.2 Abbott Major Business
- 2.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Abbott Recent Developments/Updates
- 2.7 Allergan
- 2.7.1 Allergan Details
- 2.7.2 Allergan Major Business
- 2.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Allergan Recent Developments/Updates
- 2.8 TEVA
- 2.8.1 TEVA Details
- 2.8.2 TEVA Major Business
- 2.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 TEVA Recent Developments/Updates
- 2.9 Mylan
- 2.9.1 Mylan Details
- 2.9.2 Mylan Major Business
- 2.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 Mylan Recent Developments/Updates
- 2.10 Novartis
- 2.10.1 Novartis Details
- 2.10.2 Novartis Major Business
- 2.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Novartis Recent Developments/Updates
- 2.11 Merck
- 2.11.1 Merck Details
- 2.11.2 Merck Major Business
- 2.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
- 2.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 Merck Recent Developments/Updates
3 Competitive Environment: Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer
- 3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Manufacturer (2019-2024)
- 3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2019-2024)
- 3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturer (2019-2024)
- 3.4 Market Share Analysis (2023)
- 3.4.1 Producer Shipments of Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
- 3.4.2 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2023
- 3.4.3 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2023
- 3.5 Benign Prostatic Hyperplasia (BPH) Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market: Region Footprint
- 3.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Market: Company Product Type Footprint
- 3.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
- 4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2019-2030)
- 4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2019-2030)
- 4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Region (2019-2030)
- 4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2019-2030)
- 4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2019-2030)
- 4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2019-2030)
- 4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2019-2030)
- 4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2019-2030)
5 Market Segment by Type
- 5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2019-2030)
- 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type (2019-2030)
- 5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Type (2019-2030)
6 Market Segment by Application
- 6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2019-2030)
- 6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application (2019-2030)
- 6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Application (2019-2030)
7 North America
- 7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2019-2030)
- 7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2019-2030)
- 7.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
- 7.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2019-2030)
- 7.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2019-2030)
- 7.3.3 United States Market Size and Forecast (2019-2030)
- 7.3.4 Canada Market Size and Forecast (2019-2030)
- 7.3.5 Mexico Market Size and Forecast (2019-2030)
8 Europe
- 8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2019-2030)
- 8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2019-2030)
- 8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
- 8.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2019-2030)
- 8.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2019-2030)
- 8.3.3 Germany Market Size and Forecast (2019-2030)
- 8.3.4 France Market Size and Forecast (2019-2030)
- 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
- 8.3.6 Russia Market Size and Forecast (2019-2030)
- 8.3.7 Italy Market Size and Forecast (2019-2030)
9 Asia-Pacific
- 9.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2019-2030)
- 9.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2019-2030)
- 9.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
- 9.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2019-2030)
- 9.3.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2019-2030)
- 9.3.3 China Market Size and Forecast (2019-2030)
- 9.3.4 Japan Market Size and Forecast (2019-2030)
- 9.3.5 South Korea Market Size and Forecast (2019-2030)
- 9.3.6 India Market Size and Forecast (2019-2030)
- 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
- 9.3.8 Australia Market Size and Forecast (2019-2030)
10 South America
- 10.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2019-2030)
- 10.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2019-2030)
- 10.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
- 10.3.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2019-2030)
- 10.3.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2019-2030)
- 10.3.3 Brazil Market Size and Forecast (2019-2030)
- 10.3.4 Argentina Market Size and Forecast (2019-2030)
11 Middle East & Africa
- 11.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2019-2030)
- 11.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2019-2030)
- 11.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
- 11.3.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2019-2030)
- 11.3.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2019-2030)
- 11.3.3 Turkey Market Size and Forecast (2019-2030)
- 11.3.4 Egypt Market Size and Forecast (2019-2030)
- 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
- 11.3.6 South Africa Market Size and Forecast (2019-2030)
12 Market Dynamics
- 12.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
- 12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
- 12.3 Benign Prostatic Hyperplasia (BPH) Drugs Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Benign Prostatic Hyperplasia (BPH) Drugs and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Benign Prostatic Hyperplasia (BPH) Drugs
- 13.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Benign Prostatic Hyperplasia (BPH) Drugs Typical Distributors
- 14.3 Benign Prostatic Hyperplasia (BPH) Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Benign Prostatic Hyperplasia (BPH) Drugs. Industry analysis & Market Report on Benign Prostatic Hyperplasia (BPH) Drugs is a syndicated market report, published as Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Benign Prostatic Hyperplasia (BPH) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
